AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday.
If you are not happy with the results below please do another search
50 search results for:
Seven biopharma companies are under new leadership. This week’s Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
As of Thursday, 4.4 million people had received redesigned COVID-19 booster shots, a few weeks into the government’s new vaccination campaign.
Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island.
U.S. President Joe Biden will announce on Friday nearly $1.5 billion to fund access to medications for opioid overdoses, sanctions against traffickers, and increased funding for law enforcement, the White House said.
The World Anti-Doping Agency will add the painkiller tramadol to the list of banned substances for athletes in competition from 2024 and has maintained its ban on cannabis after a review.
Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr, a potential treatment for complicated urinary tract infections.
For companies that are still trying to determine what digital transformation should look like within their operations, they should look to Ireland where companies are using new and disruptive technology to transform product innovation, manufacturing operations and sustainability efforts in life sciences.
Britain’s health minister on Thursday pledged to cut waiting times for doctors’ appointments and launched a fund to support social care, in a plan that drew criticism for not doing enough to solve a staffing crisis in the National Health Service (NHS).